Our findings provide a novel mechanism of ERα-mediated chemoresistance and suggest that WBP2 might be an effective target for the development of novel therapeutic strategies to overcome multiple drug resistance in breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.